Thanks Bob.
This debate over which funding goes in the income statement, and which goes in the balance sheet, was interesting to me. I was corrected by three posters in a friendly manner, and I appreciated it. It was unfortunate when my misunderstanding, of where the funding was logged, resulted in personal attacks. I'd hate to see what happens to someone, on this thread, that makes a real serious misstatement! <g>
<< now the company is about to come of age and they need cash to roll out their products. so the warrant conversion is very important and is another vote of confidence in LGND by large institutional holders. >>
I agree. Good point.
I guess everyone is waiting with baited breath for the FDA decision on ONTAK and Panretin Gel. I went back into the press releases to dig out the trial results on ONTAK, in order to re-visit how effective ONTAK was in treating CTCL. Here is what I found. Sounds pretty good to me!
<================================================================>
The Phase III study included 71 patients who had failed an average of five previous therapies. The Phase III intent-to-treat analysis showed that overall, 30 percent of patients treated with ONTAK demonstrated responses of 50 percent or greater reduction in tumor burden -- a response rate consistent with the earlier Phase I/II study.
Approximately 10 percent of the patients (7 of 71) showed a complete resolution of all evidence of tumor for at least six weeks. The median time of first response for all patients occurred during the second cycle of therapy, and seven patients with partial responses continued to evolve with further treatment to complete responses. These
patients received an additional one to seven courses of treatment following partial response prior to reaching their complete response.
In addition, the study included secondary endpoints that included assessment of CTCL disease symptoms that were independently evaluated by patients themselves. Symptom improvement was reported by all patients identified as responders. Symptomatic improvement was also reported in 80 percent of patients who did not achieve an objective clinical response.
<==================================================================>
Are these results good enough to get approval?
Regards, and good luck, Bob
|
